Fig. 7: Capacity of the FSCNO-DH nanoparticles in overcoming drug resistance and destroying drug-resistant tumors in vivo. | Nature Communications

Fig. 7: Capacity of the FSCNO-DH nanoparticles in overcoming drug resistance and destroying drug-resistant tumors in vivo.

From: Carbon nano-onion-mediated dual targeting of P-selectin and P-glycoprotein to overcome cancer drug resistance

Fig. 7

a–c Growth curves (a), gross images (b), and weight (c) of NCI/ADR-RES, A2780ADR, and OVCAR-8 tumors with or without (W/O) co-injection of aHUVECs (With EC or W/O EC) in mice with various treatments, showing augmented antitumor efficacy of the FSCNO-DH+L treatments for all the three different types of tumors. This is due to the capability of the FSCNO-DH nanoparticles in targeting tumor vasculature and enhancing the targeted delivery of HM to inhibit the efflux pump in drug-resistant tumor when combined with the NIR laser irradiation. Error bars represent ± s.d. (n = 4 mice for each group) and statistical significance was assessed by unpaired two-sided Student t-test. d Representative images of hematoxylin and eosin (H&E) stained tumor tissues collected after sacrificing the mice on day 49 for the NCI/ADR-RES and OVCAR-8 groups and on day 16 for the A2780ADR group.

Back to article page